Miravant starts phase III restaporfin trials

April 1, 2005

Santa Barbara, CA—Miravant Medical Technologies will conduct phase III clinical trials for rostaporfin (PHOTREX) at 50 investigational sites in central and eastern Europe and the United Kingdom to evaluate a range of patients with wet age-related macular degeneration.

Santa Barbara, CA-Miravant Medical Technologies will conduct phase III clinical trials for rostaporfin (PHOTREX) at 50 investigational sites in central and eastern Europe and the United Kingdom to evaluate a range of patients with wet age-related macular degeneration.

The FDA will review the randomized, placebo-controlled trial under a Special Protocol Assessment.

The company plans to conduct a primary efficacy endpoint analysis at 12 months of about 600 patients.